BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Exosomes

The Forgotten Ones. Will Long-Haulers Be the Next Public Health Crisis?

January 12, 2021 By Cade Hildreth (CEO) Leave a Comment

Organicell Long Haulers

A LIVE ONLINE DISCUSSION ON COVID-19 LONG-HAULERS HOSTED BY ORGANICELL REGENERATIVE MEDICINE, INC.

Miami Beach, Florida, January 12th, 2021 — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) (the “Company” or “Organicell”), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies will host a live online discussion on the topic of COVID-19 long-haulers on Wednesday, January 13th at 7 P.M. EST. [Read more…]

Filed Under: Exosomes, Press Releases

CILOA creates its new GMP-compliant production unit

December 16, 2020 By Cade Hildreth (CEO)

Ciloa

The French biotech company Ciloa creates its new GMP-compliant production unit as part of the development of a new generation of exosome-based vaccines and therapeutic vectors.

  • This first production unit is designed to meet GMP (Good Manufacturing Practices) standards, thereby ensuring the autonomy of Ciloa in the development of its biomanufacturing infrastructure and in the progress towards its future clinical studies.
  • The technology developed by Ciloa uses exosomes, small nanovesicles capable of transporting therapeutic proteins, for the development of a new generation of treatments and vaccines, notably in Covid-19 disease.

[Read more…]

Filed Under: Exosomes, Press Releases

Exosomes: Company Spotlights from “A” to “Z”

December 7, 2020 By Cade Hildreth (CEO)

Exosomes

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.

In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.

With at least 13,703 scientific articles published about exosomes and 169 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. [Read more…]

Filed Under: Exosomes Tagged With: exosomes

EVerZom raises €1.1M to industrialize its exosome biomanufacturing platform

November 30, 2020 By Cade Hildreth (CEO)

EVerZom Exosome Biomanufacturing-platform
EVerZom’s ambition is to transform regenerative medicine and the field of biotherapies thanks to these «super» biological nanoparticles, the exosomes.

Paris, November 30, 2020 — EVerZom, a biopharmaceutical company specialized in the bioproduction of exosomes, announced today that it has raised €1.1 million in funding from institutional and private investors to develop its exosome bioproduction platform. This funding will speed up the platform development and scale-up, with the objective to allow routine clinical grade production by 2022. [Read more…]

Filed Under: Exosomes, Press Releases Tagged With: exosomes

Organicell Announces Additional Site for Phase I/II Clinical Trial of Zofin™ for Treatment of COVID-19

November 20, 2020 By Cade Hildreth (CEO)

Organicell Larkin Hospital

Miami, FL (November 18, 2020) – Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I/II clinical trial for the use of its Zofin™ therapeutic in treatment of COVID-19. [Read more…]

Filed Under: Exosomes, Press Releases

  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    تم التقييم 0 من 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    تم التقييم 0 من 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    تم التقييم 0 من 5
    $397 $297

Featured Posts

Jellagen launches JellaGel™, the first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix

Celularity Gx Acquisition

Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy

Helixmith Tadios

Helixmith Announces the Development of Botanical Therapeutic Product for Respiratory Diseases, TADIOS

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.